[1].Partridge A, Niman SM, Ruggeri M, et al. Pregnancy Outcome and Safety of Interrupting Therapy for women with endocrine responsIVE breast cancer: Primary Results from the POSITIVE Trial (IBCSG 48-14 / BIG 8-13).2022 SABCS. GS4-09....
Follow-up results from the POSITIVE trial showed that breastfeeding is achievable for patients with HR-positive breast cancer who conceived during a break from endocrine therapy. Fedro Peccatori, MD, PhD Breastfeeding has been demonstrated to be feasible for patients with hormone recept...
Trial Supports 12-Month Adjuvant Trastuzumab for HER2-Positive Breast CancerTarapchak
In the initial trial, 406 patients with HER2-positive breast cancer with tumors 3 cm or smaller and negative nodes received weekly paclitaxel plus weekly trastuzumab for 12 weeks, followed by trastuzumab every 3 weeks for 9 months. (There wasn’t a control group because no standard of ...
Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to have better survival outcomes than those who received placebo after a median follow-up of 6.1 years, according to the latest resul
Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N. Engl. J. Med. 387, 9–20 (2022). A phase III trial that demonstrated the efficacy of the anti-HER2 ADC, trastuzumab deruxtecan, in HER2-low metastatic breast cancer. Article CAS Google Scholar Baselga, J....
Trastuzumab deruxtecan is an antibody–drug conjugate with high extracranial activity in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. We conducted the prospective, open-label, single-arm, phase 2 TUXEDO-1 trial. We enrolled patients aged ≥18 years with HER2...
Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer Clin Cancer Res, 16 (2010), pp. 1904-1914 View in ScopusGoogle Scholar [27] A. Polychronis, H.D. Sinnett, D. Hadjiminas, H. ...
DESTINY-Breast01 trial: trastuzumab deruxtecan in previously treated HER2 positive breast cancer doi:10.21037/tbcr-21-20Translational Breast Cancer ResearchEmily B. JacksonChristine E. SimmonsKaren A. Gelmon
HER2-positive breast cancer is an aggressive subtype of breast cancer with five-year survival rates of 30% for the advanced stage. The development of anti-